Cargando…
Oral drugs in the treatment of metastatic colorectal cancer
Colorectal cancer (CRC) is one of the most common forms of cancer, with an estimated 1.36 million new cases and almost 700,000 deaths annually. Approximately 21% of patients with CRC have metastatic disease at diagnosis. The objective of this article is to review the literature on the efficacy and s...
Autores principales: | García-Alfonso, Pilar, Muñoz Martín, Andrés Jesús, Ortega Morán, Laura, Soto Alsar, Javier, Torres Pérez-Solero, Gabriela, Blanco Codesido, Montserrat, Calvo Ferrandiz, Pilar Aitana, Grasso Cicala, Silvina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111515/ https://www.ncbi.nlm.nih.gov/pubmed/33995592 http://dx.doi.org/10.1177/17588359211009001 |
Ejemplares similares
-
Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status
por: Blagoev, Krastan B., et al.
Publicado: (2017) -
Post-Chemoradiation Metastatic, Persistent and Resistant Nodes in Locally Advanced Rectal Cancer: Metrics and Their Impact on Long-Term Outcome
por: Calvo, Felipe A., et al.
Publicado: (2023) -
Cadaveric Adipose-Derived Stem Cells for Regenerative Medicine and Research
por: Milián, Lara, et al.
Publicado: (2023) -
Lobular Endocervical Glandular Hyperplasia, a mimicker and potential pitfall for HPV-independent well differentiated Gastric-type Endocervical Adenocarcinoma: Case report and literature review focusing on histology, immunophenotype, and molecular findings
por: Molero, Aida, et al.
Publicado: (2023) -
Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
por: García‐Alfonso, Pilar, et al.
Publicado: (2018)